Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for process/pmg6 returned no results
Showing 1966 to 1980 of 2854 results for process

  1. Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]

    In development Reference number: GID-TA11443 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. AlignRT in breast cancer radiotherapy (MIB157)

    NICE has developed a medtech innovation briefing (MIB) on AlignRT in breast cancer radiotherapy .

    Medtech innovation briefing
    Published
    24 August 2018

  3. LiMAx system for assessing the functional capacity of the liver (MIB168)

    NICE has developed a medtech innovation briefing (MIB) on LiMAx system for assessing the functional capacity of the liver .

    Medtech innovation briefing
    Published
    16 January 2019

  4. Patient Status Engine for wireless monitoring of vital signs (MIB271)

    NICE has developed a medtech innovation briefing (MIB) on the Patient Status Engine for wireless monitoring of vital signs .

    Medtech innovation briefing
    Published
    10 August 2021

  5. Lung texture analysis for measuring interstitial lung diseases (MIB272)

    NICE has developed a medtech innovation briefing (MIB) on lung texture analysis for measuring interstitial lung diseases .

    Medtech innovation briefing
    Published
    10 August 2021

  6. Ambu aScope 4 RhinoLaryngo for visualising upper airways during rhinolaryngoscopy (MIB316)

    NICE has developed a medtech innovation briefing (MIB) on Ambu aScope 4 RhinoLaryngo for visualising upper airways during rhinolaryngoscopy .

    Medtech innovation briefing
    Published
    14 February 2023

  7. ProciseDx point-of-care platform for inflammatory bowel disease (MIB302)

    NICE has developed a medtech innovation briefing (MIB) on ProciseDx point-of-care platform for inflammatory bowel disease .

    Medtech innovation briefing
    Published
    12 July 2022

  8. Pegvaliase for treating phenylketonuria [ID1110]

    Discontinued Reference number: GID-TA10345

    Technology appraisal guidance
    Discontinued

  9. Bevacizumab for untreated malignant pleural mesothelioma [ID1183]

    Discontinued Reference number: GID-TA10197

    Technology appraisal guidance
    Discontinued

  10. Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]

    In development Reference number: GID-TA10667 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Bempegaldesleukin with nivolumab for untreated unresectable or metastatic melanoma

    Discontinued Reference number: GID-TA10970

    Technology appraisal guidance
    Discontinued

  12. Erlotinib in combination with bevacizumab for the maintenance treatment of advanced or metastatic non-small cell lung cancer [ID44]

    Discontinued Reference number: GID-TA11206

    Technology appraisal guidance
    Discontinued

  13. Erlotinib in combination with bevacizumab for the second line treatment of advanced or metastatic non-small cell lung cancer [ID43]

    Discontinued Reference number: GID-TA11207

    Technology appraisal guidance
    Discontinued

  14. Masitinib for previously treated moderate Crohn's disease [ID1239]

    Discontinued Reference number: GID-TA11188

    Technology appraisal guidance
    Discontinued

  15. Multiple myeloma (untreated) - carfilzomib (with melphalan and prednisone) [ID1133]

    Discontinued Reference number: GID-TA11210

    Technology appraisal guidance
    Discontinued